Polyrizon Ltd.
PLRZHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePolyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. Valued at $25.3M, PLRZ is a micro-cap name in its sector. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Market Cap
$25.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-4.90
EPS (Fwd)
—
ROE
-25.4%
ROA
-28.9%
Cash
$12.3M
Total Debt
$0
Free CF
-$2.6M
52W Change
55.1%
Annual Financials
Cash vs Debt
Where PLRZ stands vs its 150-day and 200-day moving averages
As of the July 8, 2026 close, PLRZ finished 17.85% above its 150-day moving average ($12.94) and 36.28% above its 200-day moving average ($11.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PLRZ overbought or oversold?
At the July 8, 2026 close, PLRZ's RSI(14) was 74.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Polyrizon Ltd. reports $12.3M in cash and $0 in total debt. Free cash flow is running at -$2.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -25.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PLRZ.